Michelson Diagnostics Commences New Study with Melanoma Institute of Australia

The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.

Dr. Pascale Guitera, FACD, PhD will run the study evaluating VivoSight's ability to triage lesions that are superficial enough to be treated non-invasively and monitor the success, or otherwise, of non-invasive therapies.

Dr. Guitera said, "I have a passion for cutting-edge techniques that enable non-invasive diagnosis of skin tumors. VivoSight has the potential to radically change the way in which we practice to allow non-invasive treatment regimes.”